Creativity is the outcome most associated with microdosing in popular accounts and the least supported by controlled data. There is a narrow signal for cognitive flexibility in laboratory work, but measured creativity has not reliably improved in study, and expectation is especially strong in this domain — participants expected creativity gains that the measurements did not bear out. A huge volume of reports sitting on a thin evidence base, which is why it is rated anecdotal.
Why this matters
Creativity is arguably the image most people have of microdosing, which makes the mismatch between its cultural prominence and its evidentiary weakness worth stating directly. This page treats creativity as the well-reported, weakly-supported claim it is. A shorter version appears in the 90-second summary on iMicrodosing.net.
The expectation problem, in its clearest form
Creativity is where expectation and measured effect diverge most visibly. In longitudinal research, participants strongly expected gains in creativity and wellbeing — yet measured creativity was not among the variables that reliably changed. [1] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023 That gap is the single most informative finding in this domain: it shows both that expectation is large and that it is not a reliable guide to outcome. This is the same expectancy and placebo problem that runs through the wider use-case literature, and it is more acute here than for better-evidenced uses such as anxiety: because creativity is so culturally tied to microdosing, the expectation people bring is unusually strong, which makes self-reported creative benefit especially difficult to take at face value.
What does have some support
The aspect with the most support is cognitive flexibility — the capacity to shift between ideas, categories, or perspectives. The systematic review notes that laboratory studies more often detect changes in perception, attention and focus, time estimation, and certain cognitive measures than in higher-order creative performance, and a later review of controlled studies registers some genuine drug-versus-placebo effects on low-level cognitive and physiological measures. [2] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 [3] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831 But cognitive flexibility is narrower than “creativity” as people usually mean it — producing valuable novel work — and the broader creative-performance claims remain weakly evidenced. Productivity, as a distinct outcome, has very limited controlled evidence and relies primarily on subjective self-report; the closely related claims about focus and task initiation sit in the same lightly-evidenced, highly-variable territory.
- Expectation outruns measurement
The defining creativity finding: people expected creativity gains that measured creativity did not show, making this the clearest case of expectation exceeding effect. [1] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023
- Cognitive flexibility vs. creativity
The narrow signal is for shifting between ideas or perspectives, not for higher-order creative output. The two are often conflated; only the narrower one has lab support. [2] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Productivity rests on self-report
Productivity as a distinct outcome has very limited controlled evidence and relies primarily on subjective self-report.
Three things to keep straight
First, creativity is the most reported microdosing benefit and among the least supported by controlled data. Second, the one robust comparison found expected creativity gains that measured creativity did not show. [1] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023 Third, the narrow cognitive-flexibility signal should not be inflated into a broad claim about creative output, and productivity rests on self-report alone.
Where creativity sits among the use cases
Creativity sits in the anecdotal tier — the largest volume of reports, the thinnest evidence base. It is the counterpart to anxiety at the other end of the ordering: where anxiety has consistent reports and a clear mechanism, creativity has abundant reports and a documented expectation problem. The reviewers place cognition and creativity among the well-reported, weakly-supported areas most in need of controlled study. [2] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
Does microdosing boost creativity?
Creativity is the most widely reported microdosing benefit and the least formally studied. There is some lab support for cognitive flexibility, but measured creativity has not reliably improved in controlled study, and expectation is especially strong here. [2] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
Didn't a study show people expected creativity gains that didn't materialise?
Yes. In longitudinal research, participants strongly expected creativity gains, yet measured creativity was not among the variables that reliably changed — a clear example of expectation outrunning measured effect. [1] Observational A systematic study of microdosing psychedelics doi:10.1371/journal.pone.0211023
What about cognitive flexibility specifically?
Cognitive flexibility — shifting between ideas or perspectives — has the most support, with some laboratory signals. But it is narrower than “creativity” as usually meant, and the broader creative-performance claims remain weakly evidenced. [3] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831
In summary
Creativity is the most iconic microdosing claim and one of the least substantiated. The narrow signal for cognitive flexibility is real but far smaller than the cultural image of enhanced creative output, and the one rigorous comparison found that expected creativity gains did not show up in measurement — making this the clearest example of expectation exceeding effect. The defensible reading is that creativity is the most reported and least established use case, and that the gap between the two is itself the most interesting thing about it.